Zimmer Biomet
About the company
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Price below modeled range
5-year outlook: Not shown because confidence is low: Earnings-based DCF disagrees strongly.
Why: Free cash flow is positive and in line with earnings, and the dividend is small, so a cash-flow DCF fits best.
The range depends on model assumptions and data; it is not a prediction or investment advice.
After signing in, return here and select “Add to watchlist”. Saving companies requires a verified email address.
Market price below modeled range
Showing the EV/Sales (Rule of 40) you selected on the company card, using 4.93% growth, 2.9% terminal growth and 10.5% discount. The range varies these assumptions slightly; it is illustrative, not investment advice.
Assumptions: growth 4.93%, discount rate 10.50%, terminal growth 2.90% (sector defaults). See a worked example.
Blended growth assumption: 4.9% (sector default 6.8%, own revenue history 5.8%, analyst revenue consensus 3.5%).
Analyst consensus expects revenue growth of 3.5% a year; the growth assumption used is 4.9%.
Adjust assumptions
Show the recommended model instead
Why this model: Free cash flow is positive and in line with earnings, and the dividend is small, so a cash-flow DCF fits best.
Compare models- Recommended: Free-cash-flow DCF — USD 107.34 (+0.5%)
-
EPS-based Gordon proxy
— USD 54.29 (-49.2%)
Not used: Treats all earnings as if paid out and ignores the cash kept for reinvestment, so it overstates value for companies that retain most profit.
-
DCF (trailing free cash flow)
— USD 119.74 (+12.1%)
Not used: Free cash flow is 2.7x net income, which usually means costs such as lease payments sit outside operating cash flow, so it may be overstated.
-
FCFF (steady state)
— USD 106.90 (+0.0%)
Not used: Free cash flow is 2.7x net income, which usually means costs such as lease payments sit outside operating cash flow, so it may be overstated.
-
EV/EBITDA (12x)
— USD 106.21 (-0.6%)
Not used: Used only when free cash flow is far below earnings even after averaging three years; a fixed 12x multiple also ignores sector differences.
-
Fade DCF (10-year growth fade)
— USD 119.25 (+11.6%)
Not used: Free cash flow is 2.7x net income, which usually means costs such as lease payments sit outside operating cash flow, so it may be overstated.
-
EV/Sales (Rule of 40)
— USD 245.90 (+130.1%)
Not used: Used only for technology and communication companies whose cash-flow value is far below the price.
| Bear USD 175.15 | 39.0% |
| Base USD 245.90 | 56.5% |
| Bull USD 316.66 | 66.3% |
Margin = (value − price) / value, so it is measured against the value and reads lower than the upside to value, which is measured against the price. Positive means the price is below that case.
Track record: see the methodology page for how this model has performed historically, including its limits. Treat it as a screen, not a forecast.
Price history and fair value
5 years price change: -16.38% · USD 106.85 · Market data through 05 Nov 2026 ; dashed line is today’s model base value (USD 245.90). The fair value is today’s estimate, not what the model said in the past.
Saved price history is current through 05 Nov 2026; last refreshed 06 Nov 2026 18:44 (2 hours, 28 minutes ago).
08 Nov 2021Range USD 81.90 – 141.2205 Nov 2026
Latest news
Headlines provided by EODHD. Articles may mention multiple companies and are not investment recommendations.
More detail: quality, peers, price history, dividends and financials
Quality score: 90 / 100
Five equal checks on reported history: profitability, cash generation, revenue growth, balance sheet and margins. It describes business quality, not whether the price is attractive.
| Profitability | 5 of 5 years profitable | 20 / 20 |
| Cash generation | free cash flow positive in 5 of 5 years | 20 / 20 |
| Growth | revenue +5.4% a year | 20 / 20 |
| Balance sheet | net debt 3.1x EBITDA | 10 / 20 |
| Margins | EBITDA margin 27% | 20 / 20 |
Peers in Health Care
Same-sector companies with a valuation, most undervalued first. Compare the margin of safety, yield and quality score side by side.
| Company | Price | Margin of safety | P/E | P/B | Yield | Quality |
|---|---|---|---|---|---|---|
| ZBH (this company) | USD 106.85 | 0.5% | 26.6 | 1.6 | 0.9% | 90 |
| CNC Centene Corporation | USD 74.17 | 41.6% | 25.1 | 1.7 | – | 72 |
| ZEAL.CO Zealand Pharma A/S | DKK 232.90 | 36.5% | 6.0 | 0.9 | – | 72 |
| CI Cigna | USD 301.48 | 28.8% | 12.4 | 1.9 | 2.0% | 70 |
| CVS CVS Health | USD 81.33 | 12.4% | 9.5 | 1.3 | 3.3% | 70 |
| BAVA.CO Bavarian Nordic A/S | DKK 241.00 | 12.0% | 11.9 | 1.4 | – | 92 |
| AMP.MI Amplifon S.p.A. | EUR 11.17 | 8.7% | 41.1 | – | 2.6% | 72 |
| GSK.L GSK plc | GBP 18.90 | -5.4% | 17.7 | 4.1 | 3.5% | 92 |
| SAN.PA Sanofi | EUR 83.74 | -5.5% | 13.1 | – | 4.7% | 92 |
| Peer median | 12.7 | 1.5 | ||||
Dividends
Paid in the last 12 months: USD 0.96 per share · yield 0.90% at the current price.
| Year | Dividends per share |
|---|---|
| 2026 (so far) | 0.720 |
| 2025 | 0.960 |
| 2024 | 0.960 |
| 2023 | 0.960 |
| 2022 | 0.960 |
| 2021 | 0.932 |
Trailing 12-month financials
TTM through 30 Sep 2026 · quarterly EODHD data · data downloaded 06 Nov 2026 16:36
| Revenue | USD 8,570,400,000 |
|---|---|
| EBITDA | USD 2,286,000,000 |
| EBIT | USD 1,179,200,000 |
| Net income | USD 767,500,000 |
| Free cash flow | USD 2,035,900,000 |
| Capital expenditures | USD 534,800,000 |
| Debt | USD 7,504,200,000 |
| Cash | USD 399,900,000 |
| Working capital | USD 1,626,600,000 |
| Shares outstanding | 191,400,000 |
| Reported dividends per share | USD 0.9754 |